Retraction: Optimising Extended Adjuvant Neratinib Use in HER2+/HR+ Early Breast Cancer: Memo For Nurses - European Medical Journal

This site is intended for healthcare professionals

Continue

Retraction: Optimising Extended Adjuvant Neratinib Use in HER2+/HR+ Early Breast Cancer: Memo For Nurses

Oncology

Author: EMJ

Citation: EMJ Oncol. 2026; https://doi.org/10.33590/emjoncol/T7IOP6HT 

Original publication¹

Pierre Fabre has requested the removal of this sponsored material as its 2-year validity period has expired.

Reference:

1. EMJ Oncol. 2024; DOI/10.33590/emjoncol/10309270. https://doi.org/10.33590/emjoncol/10309270 

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

We’ve noticed you’re accessing
from North/South America.